SCHEMBL3017974

SCHEMBL3017974

CC1(Cc2ccccc2)COc2cc(C(=O)O)ccc21.NC(=O)N1CCCCC1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 3/20 0.78
CNR1 P21554 1/20 0.38
CYP2C9 P11712 3/20 0.37
CYP2D6 P10635 2/20 0.37
HIF1A Q16665 1/20 0.37
TSHR P16473 3/20 0.36
ALDH1A1 P00352 3/20 0.36
RARA P10276 2/20 0.36
RARB P10826 2/20 0.36
RARG P13631 2/20 0.36
GAA P10253 1/20 0.35
HPGD P15428 3/20 0.35
CYP1A2 P05177 2/20 0.35
CYP3A4 P08684 2/20 0.35
CYP2C19 P33261 2/20 0.35
RECQL P46063 1/20 0.35
LTB4R Q15722 1/20 0.35
LTB4R2 Q9NPC1 1/20 0.35
LMNA P02545 1/20 0.35
POLB P06746 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3024232 0.92 CNR2 (0.66) CNR2CNR1CYP2C9CYP2D6HIF1A
SCHEMBL15428814 0.88 CNR2 (1.00) CNR2CNR1CYP2C9CYP2D6TSHR
SCHEMBL17889676 0.88 CNR2 (1.00) CNR2CNR1CYP2C9CYP2D6TSHR
SCHEMBL3016208 0.88 CNR2 (1.00) CNR2CNR1CYP2C9CYP2D6TSHR
SCHEMBL3020924 0.87 CNR2 (0.71) CNR2TSHRALDH1A1RARARARB
SCHEMBL13211746 0.79 CNR2 (0.84) CNR2CNR1CYP2C9CYP2D6TSHR
SCHEMBL14942535 0.78 CNR2 (0.82) CNR2CNR1CYP2C9CYP2D6TSHR
SCHEMBL13211749 0.78 CNR2 (0.82) CNR2CNR1CYP2C9ALDH1A1GAA
SCHEMBL3019867 0.78 CNR2 (0.71) CNR2TSHRALDH1A1RARARARB
SCHEMBL3007800 0.78 CNR2 (0.81) CNR2CYP2C9CYP2D6TSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230404990-A1 NEUROPROTECTIVE CB2 RECEPTOR AGONISTS CLEVELAND CLINIC FOUND (US) 2023-12-21 US disclosed
US-20220047568-A1 NEUROPROTECTIVE CB2 RECEPTOR AGONISTS CLEVELAND CLINIC FOUND (US) 2022-02-17 US disclosed
US-11160798-B2 Neuroprotective CB2 receptor agonists THE CLEVELAND CLINIC FOUNDATION (US) 2021-11-02 US disclosed
US-10835521-B2 Neuroprotective CB2 receptor agonists THE CLEVELAND CLINIC FOUNDATION (US) 2020-11-17 US disclosed
EP-3735239-A1 ORAL CANNABINOID RECEPTOR MODULATOR FORMULATIONS THE CLEVELAND CLINIC FOUNDATION (US) 2020-11-11 EP disclosed
US-20200087288-A1 ORAL CANNABINOID RECEPTOR MODULATOR FORMULATIONS CLEVELAND CLINIC FOUND (US) 2020-03-19 US disclosed
US-20200085811-A1 NEUROPROTECTIVE CB2 RECEPTOR AGONISTS THE CLEVELAND CLINIC FOUNDATION 2020-03-19 US disclosed
US-20190210999-A1 ORAL CANNABINOID RECEPTOR MODULATOR FORMULATIONS THE CLEVELAND CLINIC FOUNDATION 2019-07-11 US disclosed
WO-2019136331-A1 ORAL CANNABINOID RECEPTOR MODULATOR FORMULATIONS THE CLEVELAND CLINIC FOUNDATION (US) 2019-07-11 WO disclosed
US-9394267-B2 Heterocyclic modulators of cannabinoid receptors THE CLEVELAND CLINIC FOUNDATION (US) 2016-07-19 US disclosed
US-9339486-B2 Heterocyclic modulators of cannabinoid receptors THE CLEVELAND CLINIC FOUNDATION (US) 2016-05-17 US disclosed
US-20150148408-A1 HETEROCYCLIC MODULATORS OF CANNABINOID RECEPTORS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2015-05-28 US disclosed
EP-2872138-A2 NEUROPROTECTIVE CB2 RECEPTOR AGONISTS THE CLEVELAND CLINIC FOUNDATION (US) 2015-05-20 EP disclosed
WO-2014011949-A2 NEUROPROTECTIVE CB2 RECEPTOR AGONISTS THE CLEVELAND CLINIC FOUNDATION (US) 2014-01-16 WO disclosed
EP-2178371-B1 HETEROCYCLIC MODULATORS OF CANNABINOID RECEPTORS UNIV TEXAS (US) 2014-01-01 EP disclosed
US-20130237536-A1 HETEROCYCLIC MODULATORS OF CANNABINOID RECEPTORS THE CLEVELAND CLINIC FOUNDATION (US) 2013-09-12 US disclosed
US-8440832-B2 Heterocyclic modulators of cannabinoid receptors BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2013-05-14 US disclosed
US-20100204220-A1 HETEROCYCLIC MODULATORS OF CANNABINOID RECEPTORS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2010-08-12 US disclosed
EP-2178371-A1 HETEROCYCLIC MODULATORS OF CANNABINOID RECEPTORS Board of Regents, The University of Texas System (US) 2010-04-28 EP disclosed
WO-2009012221-A1 HETEROCYCLIC MODULATORS OF CANNABINOID RECEPTORS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2009-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100204220-A1 HETEROCYCLIC MODULATORS OF CANNABINOID RECEPTORS CNR1, CNR2, GPR18 CNR2 2/4885CNR1 1/4885CYP2C9 727/4885
US-11160798-B2 Neuroprotective CB2 receptor agonists CNR1, CNR2, CHRNA2 CNR2 2/4885CNR1 1/4885CYP2C9 3662/4885
US-20130237536-A1 HETEROCYCLIC MODULATORS OF CANNABINOID RECEPTORS CNR1, CNR2, GPR18 CNR2 2/4885CNR1 1/4885CYP2C9 727/4885
US-20190210999-A1 ORAL CANNABINOID RECEPTOR MODULATOR FORMULATIONS CNR1, CNR2, OPRL1 CNR2 2/4885CNR1 1/4885CYP2C9 570/4885
US-10835521-B2 Neuroprotective CB2 receptor agonists CNR1, CNR2, CHRNA2 CNR2 2/4885CNR1 1/4885CYP2C9 2948/4885
US-20220047568-A1 NEUROPROTECTIVE CB2 RECEPTOR AGONISTS CNR1, CNR2, CHRNA2 CNR2 2/4885CNR1 1/4885CYP2C9 3689/4885
US-20200085811-A1 NEUROPROTECTIVE CB2 RECEPTOR AGONISTS CNR1, CNR2, CHRNA2 CNR2 2/4885CNR1 1/4885CYP2C9 3713/4885
US-20150148408-A1 HETEROCYCLIC MODULATORS OF CANNABINOID RECEPTORS CNR1, CNR2, GPR18 CNR2 2/4885CNR1 1/4885CYP2C9 727/4885
US-20200087288-A1 ORAL CANNABINOID RECEPTOR MODULATOR FORMULATIONS CNR1, CNR2, OPRL1 CNR2 2/4885CNR1 1/4885CYP2C9 570/4885
US-20230404990-A1 NEUROPROTECTIVE CB2 RECEPTOR AGONISTS CNR1, CNR2, CHRNA2 CNR2 2/4885CNR1 1/4885CYP2C9 3079/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.